Julio Pow-Sang, MD
Advertisement
Articles by Julio Pow-Sang, MD
Advertisement
Latest Updated Articles
Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate CancerPublished: August 30th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5